Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.
Preliminary results suggest anti-COVID19 nanobodies may be effective at preventing and diagnosing infections.
Anthony Fauci, President-elect Joe Biden and senior legislators were vaccinated publicly to demonstrate their confidence in vaccine safety.
Among 64 pregnant women who tested positive for SARS-CoV-2, none of their newborns tested positive.
Study findings suggest therapeutic targets to investigate for preventing cancer relapse.
Immune cells called T cells helped prevent reinfection and may be especially important if antibody levels are low or decline over time.
The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.
Recovery and death rates were similar in people treated with the anti-malaria drug or a placebo.
A carbohydrate called heparan sulfate, found on cell surfaces, may help the new coronavirus infects cells.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
Moderna/NIH mRNA produces strong immune response in people older than 55.
Researchers hope to combine gene editing with a less toxic stem cell transplant. Findings may apply to cancer and other illnesses.
The molecular biologist was the first to clone HIV, and she helped prove that the virus causes AIDS. She also researched cancer genetics.
The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.
The FDA offers researchers new guidance to help keep trials on track.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.